Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who...

  • Sunday, December 16, 2012, 4:30 AM ET
    The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who aren't eligible for surgery. Cushing's disease is a rare hormone condition that can cause obesity, skin that bruises easily and excess hair growth. Novartis will have to carry three more analyses of Signifor for high sugar levels in patients' blood, the risks stemming from such levels, and for monitoring the long-term use of the treatment.
Track new comments on this story

This news story has 1 comment:

  •  
    Signifor is a novel cyclohexapeptidic analogue of Somatostatin and binds with high affinity to the sst5 receptor, resulting in the inhibition ACTH-release (ACTH=adrenocorticotro... hormone). Since Cushing's disease is due to overproduction of ACTH, Signifor is the drug of choice for its treatment. First generation Somatostatin analogues like Octreotide and Lanreotide had a 40-500 fold lower affinity to the sst5 receptor and hence are less effective.
    17 Dec 2012, 05:43 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »